Retatrutide: Unapproved Drug Linked to Severe Health Incidents in Australia

Drug Profile

Retatrutide is an investigational peptide drug being tested in clinical trials for weight loss. It targets three hormone pathways: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon, which influence appetite, metabolism, and blood sugar levels.

Early clinical trial data from 2023 showed that participants receiving higher doses lost more than 20% of body weight over 48 weeks. The drug is compared to semaglutide (marketed as Ozempic and Wegovy), with preliminary data suggesting potentially greater weight loss effects.

Regulatory Status

Retatrutide has not been approved for human use by any global drug regulator, including the U.S. Food and Drug Administration (FDA) or Australia's Therapeutic Goods Administration (TGA). Eli Lilly, the patent holder, has stated that retatrutide is an investigational molecule that cannot be legally sold for human use.

The TGA issued a safety warning in March 2025 regarding counterfeit weight loss drugs and has separately warned against importing and using unapproved peptide products. Products sold as retatrutide on the black market are considered counterfeit.

The experimental drug retatrutide, which has not received regulatory approval anywhere in the world, has been linked to a cluster of severe health incidents in Australia, including liver damage and kidney injury.

Reported Health Incidents in Australia

Victoria's chief health officer issued a health alert regarding six cases of acute liver toxicity associated with unapproved peptide products.

Case Reports

• A 32-year-old woman purchased retatrutide from a clinician after seeing social media posts. She injected doses on December 24 and December 28, 2024, and was hospitalized with acute liver failure less than one week later. She avoided a liver transplant but remains on steroids and has been hospitalized multiple times since.

• A woman in her 20s presented to Austin Hospital emergency department with acute liver failure after purchasing vials labeled retatrutide online following a gym recommendation. She is unlikely to require a transplant.

• A man in his 40s experienced major kidney injury from severe dehydration caused by diarrhea after taking the drug.

Reported Risks and Side Effects

Gastrointestinal Effects

Common side effects reported in clinical trials and anecdotal accounts include nausea, vomiting, diarrhea, and constipation.

Fatalities

At least one death has been reported in connection with retatrutide use, with severe diarrhea noted. The case remains under investigation.

Other Health Effects

Research suggests the drug may affect pathways in the brain related to reward and motivation, potentially influencing mood, sexual drive, and relationships, though mechanisms are not fully understood.

Risks of Unregulated Products

Products sold through unofficial channels may contain contaminants, incorrect dosages, or no active ingredient. Unsupervised use differs from controlled clinical trial conditions, which involve medical supervision and regulated dosing.

Muscle Mass Loss

Rapid weight loss can result in reduced muscle mass if not accompanied by adequate protein intake and resistance training.

"The drug is being sold through unregulated online markets and illicit channels." — The drug is compared to semaglutide, with preliminary data suggesting potentially greater weight loss effects.

Market and Usage Context

Retatrutide, sometimes called "reta," is available through illicit online markets. It is used by some gym-goers for rapid weight loss, a practice sometimes referred to as "leanmaxxing." Appetite suppression from the drug may impact social eating experiences and food enjoyment.

Medical Expert Statements

Dr. Marie Sinclair, a liver transplant specialist at Austin Hospital, expressed concern about the unknown contents of counterfeit products.

Endocrinologist Dr. Niloufar Torkamani noted that patients are inquiring about retatrutide despite its unavailability, and that low-BMI users may face risks of complications not seen in clinical trials.

This article is for informational purposes only. Consult a licensed medical professional for health advice.